Seeing Is Believing
Currently out of the existing stock ratings of Colin Bristow, 97 are a BUY (60.25%), 64 are a HOLD (39.75%).
Analyst Colin Bristow, carries an average stock price target met ratio of 64.28% that have a potential upside of 29.7% achieved within 335 days. Previously, Colin Bristow worked at UBS, BAML.
Colin Bristow’s has documented 314 price targets and ratings displayed on 23 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on ENGN, enGene Holdings Common Stock at 12-Nov-2025.
Analyst best performing recommendations are on CADL (CANDEL THERAPEUTICS).
The best stock recommendation documented was for ALXO (ALX ONCOLOGY HOLDINGS ) at 5/21/2025. The price target of $1 was fulfilled within 92 days with a profit of $0.59 (143.9%) receiving and performance score of 15.64.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 28-Jul-2017
$205
$22.5 (12.33%)
5 years 4 months 22 days ago
(05-May-2021)
3/5 (60%)
$35.09 (20.65%)
938
Hold Since 03-May-2021
$173
$-9.5 (-5.21%)
$156
5 years 4 months 24 days ago
(03-May-2021)
17/29 (58.62%)
$2.73 (1.60%)
650
Hold Since 04-Feb-2021
$190
$7.5 (4.11%)
$190
5 years 5 months 1 days ago
(26-Apr-2021)
11/14 (78.57%)
$23 (13.77%)
420
Buy Since 06-Sep-2019
$175
$-7.5 (-4.11%)
$165
5 years 7 months 23 days ago
(04-Feb-2021)
3/3 (100%)
$19.41 (12.48%)
397
Buy Since 17-Jul-2017
$166
$-16.5 (-9.04%)
$175
5 years 7 months 23 days ago
(04-Feb-2021)
32/33 (96.97%)
$10.41 (6.69%)
867